TRIM29 as a prognostic predictor for multiple human malignant neoplasms: a systematic review and meta-analysis
Metrics: PDF 615 views | HTML 1511 views | ?
Chao Liang1,*, Huiyu Dong1,*, Chenkui Miao1,*, Jundong Zhu1, Jie Wang1, Pu Li1, Jie Li1 and Zengjun Wang1
1State Key Laboratory of Reproductive Medicine and Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
*These authors contributed equally to this work
Zengjun Wang, email: email@example.com
Jie Li, email: firstname.lastname@example.org
Keywords: TRIM29; prognosis; meta-analysis; malignant neoplasm
Received: July 21, 2017 Accepted: October 28, 2017 Published: December 22, 2017
Recent studies have shown that tripartite motif-containing protein 29 (TRIM29) had prognostic values in several cancers. However, different studies have been inconsistent. We conducted a meta-analysis to elucidate the precise predictive value of TRIM29 in various human malignant disease. Eleven eligible studies with 2046 patients were ultimately enrolled in this meta-analysis. Heterogeneity between studies was assessed using I2 statistics. Pooled Hazard ratios (HRs) with 95% confidence intervals (CIs) for patient survival and disease recurrence were calculated to investigate the correlation between TRIM29 expression and cancer prognosis. The results identified an important link between upregulated TRIM29 expression and poor prognosis in patients with multiple human malignant neoplasms in terms of recurrence-free survival (RFS)/disease-free survival (DFS) (HR = 1.66, 95% CI 1.36–2.04) but favorable progression-free survival (PFS)/metastasis-free survival (MFS) (HR = 0.37, 95% CI 0.16–0.85). We found that high TRIM29 expression predicted no significant impact on overall survival (OS) (HR = 1.32, 95% CI 0.90–1.93). Subgroup analyses showed that high TRIM29 expression predicted poor OS in Asians (HR = 2.21, 95% CI 1.78–2.74) but favorable OS in Caucasian (HR = 0.47, 95% CI 0.25–0.89). TRIM29 might play an essential role in carcinogenesis of multiple human malignant neoplasms and could serve as a biomarker for the prediction of patients’ prognosis.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.